Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | BACE1 | P56817 | 5/20 | 0.50 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049427 | 1.00 | ACHE (0.50) | ACHEBACE1BCHECYP3A4CYP1A2 | |
| SCHEMBL4671277 | 0.94 | CYP1A2 (0.50) | ACHEBACE1BCHECYP3A4CYP1A2 | |
| SCHEMBL19195295 | 0.81 | ACHE (0.54) | ACHEBACE1BCHECYP3A4CYP1A2 | |
| SCHEMBL25871654 | 0.81 | CYP3A4 (0.49) | ACHEBACE1BCHECYP3A4CYP1A2 | |
| SCHEMBL23647534 | 0.81 | CYP3A4 (0.56) | ACHECYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27972174 | 0.79 | TSHR (0.49) | ACHEBACE1BCHECYP2D6ALDH1A1 | |
| SCHEMBL20895733 | 0.78 | CYP1A2 (0.42) | ACHECYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16054301 | 0.78 | CYP1A2 (0.42) | ACHECYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8603143 | 0.78 | BCHE (0.50) | ACHEBACE1BCHECYP3A4CYP1A2 | |
| SCHEMBL8570353 | 0.78 | CYP1A2 (0.42) | ACHECYP3A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1693364-B1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI SANKYO CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-7994344-B2 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090240066-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-7569599-B2 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1768987-B1 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | CUMBRE PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070117988-A1 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1693364-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20060019986-A1 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117988-A1 | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates | RAP1A, RHOA, MGMT | ACHE 1020/4885BACE1 2820/4885BCHE 2944/4885 |
| US-20090240066-A1 | INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES | RAP1A, RHOA, MGMT | ACHE 1020/4885BACE1 2820/4885BCHE 2944/4885 |
| US-20060019986-A1 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | RPS6KA1, RIF1, RPS27L | ACHE 2806/4885BACE1 4415/4885BCHE 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.